SCHEMBL570346

SCHEMBL570346

CCn1nc(-c2ccc(Oc3cn4ccccc4n3)cc2)c2ncccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.43
RAB9A P51151 7/20 0.43
SMN1; SMN2 Q16637 6/20 0.43
ALDH1A1 P00352 5/20 0.43
PKM P14618 3/20 0.43
MAPK1 P28482 2/20 0.43
KDM4E B2RXH2 6/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
EPHX2 P34913 1/20 0.38
PDE10A Q9Y233 3/20 0.38
HRH3 Q9Y5N1 2/20 0.38
MAPT P10636 3/20 0.36
LMNA P02545 3/20 0.36
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
TNNI3 P19429 1/20 0.34
CRHBP P24387 1/20 0.34
CASP1 P29466 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15065035 0.99 NPC1 (0.43) NPC1RAB9ASMN1; SMN2ALDH1A1PKM
SCHEMBL570750 0.82 PTGS2 (0.40) ALDH1A1MAPK1KDM4EPDE10AMEN1
SCHEMBL570261 0.77 MEN1 (0.44) ALDH1A1MAPK1KDM4EPDE10AMAPT
SCHEMBL10285532 0.76 KDM4E (0.38) NPC1RAB9AALDH1A1MAPK1KDM4E
SCHEMBL10285802 0.76 HRH3 (0.37) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL570539 0.76 LTA4H (0.38) PDE10A
Hydrochloric Acid SCHEMBL569058 0.76 HRH3 (0.37) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL15064484 0.75 PDE10A (0.43) NPC1RAB9AALDH1A1MAPK1KDM4E
SCHEMBL10285695 0.74 MEN1 (0.40) MAPK1KDM4EPDE10AMAPTLMNA
SCHEMBL12473757 0.73 PDE10A (0.36) ALDH1A1MAPK1KDM4EPDE10AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601192-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICALS CO (JP) 2017-03-01 EP disclosed
EP-2601192-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICALS CO (JP) 2017-03-01 EP disclosed
US-9029536-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-12 US disclosed
US-9029536-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-12 US disclosed
US-9029536-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-12 US disclosed
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-04 US disclosed
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-04 US disclosed
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-04 US disclosed
WO-2012018909-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS PDE10A, PDE3A, PDE2A NPC1 3068/4885RAB9A 64/4885SMN1; SMN2 2821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.